AbbVie controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
2024
Trade-secret lawsuit against BeiGene
AbbVie sued BeiGene, alleging that a former AbbVie scientist took confidential information that was used in developing a competing blood-cancer treatment. The allegations were disputed and remained litigation claims rather than established findings.
2022
Opioid-marketing settlement involving Allergan
AbbVie agreed to pay up to $2.37 billion to resolve U.S. litigation involving alleged opioid marketing by its Allergan unit. AbbVie denied wrongdoing.
2021
Senate investigation into tax practices
The United States Senate Finance Committee examined whether AbbVie used provisions of the 2017 tax law and offshore intellectual-property structures to reduce its U.S. tax liability.
2020
Humira nurse-ambassador allegations
AbbVie agreed to pay $24 million to resolve allegations concerning kickbacks connected with promotion of Humira through nurse-ambassador programs.
2018
TriCor marketing settlement
AbbVie agreed to pay $25 million to resolve allegations that unlawful kickback arrangements were used to promote TriCor. The resolution did not establish a criminal conviction by itself, and the company’s legal position should be distinguished from the allegations.